Sanofi buying back $1B-plus in stock; Actos suits consolidated in Louisiana;

@FiercePharma: Bristol will have a tough time replacing 'string of pearls' strategist Levin, Bloomberg says. Story | Follow @FiercePharma

> Sanofi ($SNY) repurchased €1.074 billion worth of its own shares in 2011, or about 1.61% of its capital, at an average price of €49.6 euros per share. News

> Actos-related liability lawsuits against Takeda Pharmaceutical will be consolidated in one federal court in Louisiana, a multidistrict litigation panel determined. Item

> Pfizer's ($PFE) Prevnar 13 won FDA approval for people 50 years of age and older to prevent pneumonia and other diseases caused by Streptococcus pneumoniae. Release

> Lundbeck said its new epilepsy drug Onfi is now available in the U.S. Story

> India's Lupin won FDA approval for fenofibrate tablets for use as a dietary supplement; they're a generic version of Abbott Laboratories' ($ABT) prescription drug Tricor. Piece

> India's Dr. Reddy's Laboratories launched a pain relief cream, Supamove, that it licensed from Cymbiotics. Report

Biotech News

@FierceBiotech: FDA dishes out long-awaited guidance on social media. Article | Follow @FierceBiotech

@JohnCFierce: In case you missed last week's news, Alexion scoops up promising rare disease drug in $1.08B Enobia buyout. Story | Follow @JohnCFierce

@RyanMFierce: Accelrys paying $35M cash in VelQuest buyout, expanding from R&D software to tech for drug manufacturers. Release | Follow @RyanMFierce

> Aveo cancer drug beats Nexavar in risky PhIII face-off. Article

> Alexion scoops up rare disease drug in $1.08B Enobia buyout. News

Pharma Manufacturing News

> Flu vax tool aids strain identification, timing. Story

> Hospira enters angry-investor phase of remediation. Article

> Ben Venue lengthens remediation timeline. Item

> Infant pain reliever dosing 'fix' shows label limitations. Report

> Rockline quietly recalls contaminated wipes. News

> H&P/Triad, under decree, will recondition seized wipes. More

Biotech Research News

> Fish oil wipes out leukemia in mice. News

> Researchers decode some kidney cancer secrets. Item

> Johns Hopkins tapping genomes to find out why so many African-Americans get asthma. News

Biotech IT News

> FDA dishes out long-awaited guidance on social media. Article

> Poor patient recruitment cited in call for trial disclosures. Story

And Finally...
Drug-resistant TB may be caused by patients with faster-than-normal metabolism rather than inconsistent dosing, a new study suggests. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.